芒果视频下载

成立于1998年，知名阿膠品牌，以藥業/酒業為主導，集研發/生產/經營/投資/管理于一體的綜合性集團公司，產品涵蓋了中西藥制劑/生物制藥/原料藥/保健食品等品類

1998年成立的輔仁藥業集團，是一家以藥業、酒業為主導，集研發、生產、經營、投資、管理于一體的綜合性集團公司。集團(tuan)囊括河南(nan)輔(fu)仁堂(tang)制藥(yao)(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、河南(nan)輔(fu)仁懷慶堂(tang)制藥(yao)(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、開(kai)封(feng)(feng)制藥(yao)(yao)(yao)（集團(tuan)）有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、開(kai)封(feng)(feng)豫(yu)港制藥(yao)(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、開(kai)藥(yao)(yao)(yao)集團(tuan)（開(kai)魯）制藥(yao)(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、河南(nan)同(tong)源制藥(yao)(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、輔(fu)仁醫(yi)藥(yao)(yao)(yao)科(ke)技(ji)開(kai)發(fa)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、輔(fu)仁藥(yao)(yao)(yao)業(ye)集團(tuan)醫(yi)藥(yao)(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、輔(fu)仁藥(yao)(yao)(yao)業(ye)集團(tuan)熙德隆腫瘤藥(yao)(yao)(yao)品有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、北京遠(yuan)策(ce)藥(yao)(yao)(yao)業(ye)有(you)(you)(you)限(xian)(xian)責任公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、北京輔(fu)仁瑞輝生物(wu)醫(yi)藥(yao)(yao)(yao)研(yan)究院(yuan)、上(shang)海輔(fu)仁醫(yi)藥(yao)(yao)(yao)研(yan)發(fa)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、鄭州遠(yuan)策(ce)生物(wu)制藥(yao)(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)、河南(nan)省宋(song)河酒業(ye)股份有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)及(ji)上(shang)市公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)輔(fu)仁藥(yao)(yao)(yao)業(ye)集團(tuan)制藥(yao)(yao)(yao)股份有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)等多家全資、控(kong)股子公(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)(si)(si)(si)(si)。

集團產品涵(han)蓋了(le)中西(xi)藥(yao)(yao)制(zhi)劑、生物制(zhi)藥(yao)(yao)、原料藥(yao)(yao)、保健食品等多個(ge)門類。2006年(nian)，隨著河南(nan)輔(fu)(fu)(fu)仁(ren)(ren)(ren)堂制(zhi)藥(yao)(yao)有(you)限公司成功實現上(shang)市，資本的(de)力量不僅把輔(fu)(fu)(fu)仁(ren)(ren)(ren)推向一(yi)個(ge)飛速發展(zhan)時期，其行(xing)業(ye)(ye)地位亦逐步提(ti)升。2017年(nian)12月(yue)29日(ri)，輔(fu)(fu)(fu)仁(ren)(ren)(ren)藥(yao)(yao)業(ye)(ye)重(zhong)大資產重(zhong)組成功，把集團優(you)質(zhi)資產——開封制(zhi)藥(yao)(yao)（集團）有(you)限公司置入輔(fu)(fu)(fu)仁(ren)(ren)(ren)藥(yao)(yao)業(ye)(ye)，使(shi)輔(fu)(fu)(fu)仁(ren)(ren)(ren)藥(yao)(yao)業(ye)(ye)跨入一(yi)個(ge)新(xin)的(de)發展(zhan)階(jie)段。

“品種(zhong)(zhong)為核心，并(bing)購為主線(xian)”的早期發(fa)(fa)展戰(zhan)略讓輔(fu)仁(ren)藥業集(ji)團的產能和產品線(xian)在(zai)很(hen)短時(shi)間內飛速發(fa)(fa)展。迄今(jin)，輔(fu)仁(ren)藥業集(ji)團已擁有(you)水針劑(ji)(ji)、凍干粉針劑(ji)(ji)、口服(fu)固體制劑(ji)(ji)等(deng)20多個(ge)劑(ji)(ji)型，1000余個(ge)品種(zhong)(zhong)；制劑(ji)(ji)綜(zong)合產能位居(ju)全(quan)(quan)國(guo)制藥行業前茅。2017新版(ban)醫保(bao)目錄輔(fu)仁(ren)藥業集(ji)團共入選578個(ge)品種(zhong)(zhong)，較2009版(ban)目錄增(zeng)(zeng)加品種(zhong)(zhong)165個(ge)，增(zeng)(zeng)幅39.95%，其中甲類入選364個(ge)，增(zeng)(zeng)幅42.754%，乙類入選214個(ge)，增(zeng)(zeng)幅35.44%。在(zai)國(guo)家衛健委正式發(fa)(fa)布《國(guo)家基本藥物目錄（2018年版(ban)）》中，輔(fu)仁(ren)藥業集(ji)團共有(you)阿莫西(xi)林克拉(la)維酸鉀干混(hun)懸(xuan)劑(ji)(ji)、奧美拉(la)唑腸溶膠囊、注射(she)用重(zhong)組人干擾(rao)素α2b等(deng)262個(ge)品規榜上(shang)有(you)名(ming)，較2012版(ban)目錄增(zeng)(zeng)加75個(ge)，增(zeng)(zeng)幅40.11%，成為全(quan)(quan)國(guo)入選品種(zhong)(zhong)較多的制藥企業之一(yi)。

輔仁藥(yao)業(ye)集團一直遵循“濟世(shi)藥(yao)為輔、惠(hui)民志在仁”的企(qi)(qi)業(ye)理念(nian)，始(shi)終貫徹“產量讓位于質(zhi)量、成本讓位于質(zhi)量”的質(zhi)量管理方針，本著(zhu)“和而不同、化繁(fan)為簡、務實創新、濟世(shi)惠(hui)民”的企(qi)(qi)業(ye)價值觀，把(ba)“做一家(jia)實體型、科(ke)技型、國際型企(qi)(qi)業(ye)”作(zuo)為自己的企(qi)(qi)業(ye)定位，兼容并蓄，尊(zun)重規律(lv)，踐行(xing)規則。

在企(qi)業并(bing)購的(de)(de)同(tong)時(shi)，輔(fu)仁(ren)藥業集(ji)團(tuan)投入巨資加強企(qi)業創(chuang)(chuang)新平(ping)(ping)臺(tai)(tai)建設，戰略(lve)性布局鄭(zheng)州技(ji)術研(yan)(yan)(yan)(yan)發(fa)和國際化合作(zuo)(zuo)及(ji)產(chan)業化服務平(ping)(ping)臺(tai)(tai)、北(bei)京創(chuang)(chuang)新研(yan)(yan)(yan)(yan)發(fa)平(ping)(ping)臺(tai)(tai)、上海醫藥研(yan)(yan)(yan)(yan)發(fa)創(chuang)(chuang)新國際合作(zuo)(zuo)平(ping)(ping)臺(tai)(tai)、美國新澤(ze)西、費城(cheng)研(yan)(yan)(yan)(yan)發(fa)平(ping)(ping)臺(tai)(tai)四(si)大(da)研(yan)(yan)(yan)(yan)發(fa)創(chuang)(chuang)新平(ping)(ping)臺(tai)(tai)，以及(ji)中醫藥大(da)數據(ju)及(ji)人工(gong)智能中醫研(yan)(yan)(yan)(yan)發(fa)平(ping)(ping)臺(tai)(tai)，更(geng)將在小(xiao)分(fen)子化學藥、大(da)分(fen)子生物藥研(yan)(yan)(yan)(yan)發(fa)和中醫藥傳承創(chuang)(chuang)新方向同(tong)時(shi)發(fa)力，開辟以研(yan)(yan)(yan)(yan)發(fa)驅動(dong)創(chuang)(chuang)新的(de)(de)發(fa)展新路(lu)徑(jing)。

目前，輔(fu)仁(ren)藥(yao)業(ye)集團(tuan)(tuan)支(zhi)持創(chuang)新研發面積達11.3萬平(ping)方米，研發創(chuang)新隊(dui)伍近1500人。同(tong)時，秉承“中國市場、輔(fu)仁(ren)平(ping)臺(tai)、全球資源”的(de)發展(zhan)策略，輔(fu)仁(ren)藥(yao)業(ye)集團(tuan)(tuan)實(shi)現了(le)從“百姓藥(yao)、輔(fu)仁(ren)造”到“創(chuang)新藥(yao)、輔(fu)仁(ren)造”的(de)可持續(xu)發展(zhan)跨越，為客戶及整個社會創(chuang)造價值，健康中國，服務世(shi)界。